Rebuild Cells, Rescue Lives

Founded in 2019, Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics) is a biotechnology company focused on the research, development and commercialization of cell therapies for the treatment of solid tumors. Leveraging our proprietary DeepTIL™ Cell Enrichment and Expansion Platform, NovaGMP™ Non-Viral Gene-Modification Platform, and RiverTIL™ In Vivo TIL Platform, we innovate at the source to enhance product efficacy and safety, and significantly reduce production and overall treatment costs to improve TIL therapy accessibility.

Focused on high-incidence tumors and hard-to-treat tumors, we have developed a pipeline of first-in-class and best-in-class autologous natural and gene-modified TIL therapies, covering adjuvant early treatment to later-line advanced therapy across multiple disease stages and treatment settings.

GC101, is the world's first TIL therapy that does not require high-intensity lymphodepletion chemotherapy or the use of IL-2 administration. Expected to be China's first approved TIL therapy, it provides sustained clinical benefits to melanoma, NSCLC and other patients who have failed multiple lines of treatment. GC101 registrational Phase II clinical data results have been included in the latest breakthrough abstract by the American Society of Clinical Oncology (ASCO) .